Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Active:	No
Cancer Type:	Breast Cancer Unknown Primary	NCT ID:	NCT05382286
Trial Phases:	Phase III	Protocol IDs:	GS-US-592-6173 (primary) NCI-2022-05480 2021-005742-14 jRCT2041220123 KEYNOTE-D19
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Gilead
NCI Full Details:	http://clinicaltrials.gov/show/NCT05382286

Summary

The primary objective of this study is to compare the progression-free survival (PFS)
between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's
choice (TPC) and pembrolizumab in participants with previously untreated, locally
advanced inoperable or metastatic triple-negative breast cancer, whose tumors express
programmed cell death ligand 1 (PD-L1).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.